Safety and efficacy of artemether-lumefantrine therapy for Intermittent Preventive Treatment in pregnancy in Uganda
Completed
- Conditions
- Malaria in pregnancyInfections and InfestationsMalaria
- Registration Number
- ISRCTN12394097
- Lead Sponsor
- ICEF/UNDP/World Bank/WHO Special Programme for Research and Training in Tropical Diseases (TDR)
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- Female
- Target Recruitment
- 1664
Inclusion Criteria
1. Pregnant with a gestational age between 20 to 28 weeks
2. Residing within a radius of 20 miles from the hospital
3. Attending AnteNatal Clinic (ANC) and has not yet received regular programme IPTp with SP
4. Attending ANC and last received anti-malarial treatment greater than one month ago
5. Gives informed consent for study participation
6. Able to come for follow-up
Exclusion Criteria
1. Known allergy to SP or artemether-lumefantrine
2. Previously diagnosed with Glucose-6-phosphate dehydrogenase deficiency
3. Presently ill with a medical condition requiring admission to hospital
4. Known patient with cardiac disease or arrhythmia
5. Intrauterine foetal death in the current pregnancy
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method